JP2019517469A - ピプラドロールを用いる行動症候群の治療方法 - Google Patents

ピプラドロールを用いる行動症候群の治療方法 Download PDF

Info

Publication number
JP2019517469A
JP2019517469A JP2018561714A JP2018561714A JP2019517469A JP 2019517469 A JP2019517469 A JP 2019517469A JP 2018561714 A JP2018561714 A JP 2018561714A JP 2018561714 A JP2018561714 A JP 2018561714A JP 2019517469 A JP2019517469 A JP 2019517469A
Authority
JP
Japan
Prior art keywords
pipradolol
pharmaceutically acceptable
methods
disorder
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018561714A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019517469A5 (enExample
Inventor
マシュー・デューリング
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ovid Therapeutics Inc
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of JP2019517469A publication Critical patent/JP2019517469A/ja
Publication of JP2019517469A5 publication Critical patent/JP2019517469A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2018561714A 2016-05-26 2017-05-25 ピプラドロールを用いる行動症候群の治療方法 Pending JP2019517469A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662341855P 2016-05-26 2016-05-26
US62/341,855 2016-05-26
PCT/US2017/034443 WO2017205606A1 (en) 2016-05-26 2017-05-25 Methods of treating behavioral syndromes using pipradrol

Publications (2)

Publication Number Publication Date
JP2019517469A true JP2019517469A (ja) 2019-06-24
JP2019517469A5 JP2019517469A5 (enExample) 2020-07-02

Family

ID=60408578

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018561714A Pending JP2019517469A (ja) 2016-05-26 2017-05-25 ピプラドロールを用いる行動症候群の治療方法

Country Status (10)

Country Link
US (3) US9827233B1 (enExample)
EP (1) EP3439657A4 (enExample)
JP (1) JP2019517469A (enExample)
KR (1) KR20190013737A (enExample)
CN (1) CN109414435A (enExample)
AU (1) AU2017268795A1 (enExample)
CA (1) CA3025473A1 (enExample)
IL (1) IL262986A (enExample)
MX (1) MX2018013973A (enExample)
WO (1) WO2017205606A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108024997A (zh) 2015-07-17 2018-05-11 奥维德医疗公司 用加波沙朵治疗发育障碍的方法
US9351968B1 (en) 2015-09-09 2016-05-31 Ovid Therapeutics Inc Methods of treating developmental disorders using pipradrol
CA3025473A1 (en) * 2016-05-26 2017-11-30 Ovid Therapeutics Inc. Methods of treating behavioral syndromes using pipradrol
AU2018331326A1 (en) * 2017-09-12 2020-03-19 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of narcolepsy
EP3833351A4 (en) * 2018-09-20 2021-10-13 Ovid Therapeutics Inc. USE OF GABOXADOL TO TREAT TOURETTE SYNDROME, TICKS, AND STUTTERS
KR20210110585A (ko) 2018-11-21 2021-09-08 썰테고 테라퓨틱스 아이엔씨. 자살의 위험을 감소시키고 우울증의 신속한 완화를 위한 가복사돌
MX2021007224A (es) 2018-12-17 2021-09-23 Ovid Therapeutics Inc Uso de gaboxadol para el tratamiento del trastorno del sue?o vigilia que no es de 24 horas.
GB201911056D0 (en) * 2019-08-02 2019-09-18 Sanchez Hector Mario Treatment of ADD/ADHD
IL298334A (en) 2020-05-20 2023-01-01 Certego Therapeutics Inc Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
GB202101296D0 (en) * 2021-01-29 2021-03-17 3Z Ehf Novel treatments

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010518027A (ja) * 2007-02-07 2010-05-27 ゴスフォース センター（ホールディングス）プロプライエタリー リミテッド Ａｄｈｄの治療

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2830083A (en) 1953-04-29 1958-04-08 Allied Chem & Dye Corp Production of aryloxy aliphatic carboxylic acids
US3947579A (en) 1974-06-03 1976-03-30 Nelson Research & Development Company Method and composition for potentiating neuroleptic drugs
US4084000A (en) 1975-07-16 1978-04-11 Nelson Research And Development Company Method of treating schizophrenia
US4129652A (en) 1976-08-16 1978-12-12 Nelson Research & Development Company Method for potentiating neuroleptic drugs
US5650521A (en) * 1995-12-29 1997-07-22 Guilford Pharmaceuticals Inc. Pyrrolidine derivatives
WO2009128057A2 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
EP2317845A4 (en) 2008-07-18 2011-11-09 Zafgen Inc METHOD FOR TREATING AN OVERWEIGHT OR FATABLE PERSON
FR2935611B1 (fr) 2008-09-10 2010-10-15 Commissariat Energie Atomique Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes
US20100260844A1 (en) * 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
US20120302590A1 (en) * 2009-08-13 2012-11-29 The General Hospital Corporation Methods and compositions to prevent addiction
US8853158B2 (en) 2010-05-25 2014-10-07 Institut National De La Santé Et De La Recherche Médicale (Inserm) Methods for the treatment of a feeding disorder with onset during neonate development using an agonist of the oxytocin receptor
WO2012129551A1 (en) * 2011-03-23 2012-09-27 Ironshore Pharmaceuticals & Development, Inc. Methods and compositions for treatment of attention deficit disorder
US9351968B1 (en) 2015-09-09 2016-05-31 Ovid Therapeutics Inc Methods of treating developmental disorders using pipradrol
CA3025473A1 (en) * 2016-05-26 2017-11-30 Ovid Therapeutics Inc. Methods of treating behavioral syndromes using pipradrol

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010518027A (ja) * 2007-02-07 2010-05-27 ゴスフォース センター（ホールディングス）プロプライエタリー リミテッド Ａｄｈｄの治療

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TOXICOLOGY LETTERS, vol. 212, JPN6021022379, 2012, pages 57 - 60, ISSN: 0004695754 *

Also Published As

Publication number Publication date
EP3439657A4 (en) 2019-12-18
US20180036298A1 (en) 2018-02-08
US9827233B1 (en) 2017-11-28
AU2017268795A1 (en) 2018-11-22
CN109414435A (zh) 2019-03-01
US10493069B2 (en) 2019-12-03
WO2017205606A1 (en) 2017-11-30
US20170340619A1 (en) 2017-11-30
KR20190013737A (ko) 2019-02-11
IL262986A (en) 2018-12-31
MX2018013973A (es) 2019-03-28
EP3439657A1 (en) 2019-02-13
US20190076415A1 (en) 2019-03-14
CA3025473A1 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
US10493069B2 (en) Methods of treating behavioral syndromes using pipradrol
EP2029130B1 (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
US9913833B2 (en) Methods of treating developmental disorders using pipradrol
Ye et al. Improving effects of huperzine A on spatial working memory in aged monkeys and young adult monkeys with experimental cognitive impairment
US9682069B2 (en) Methods of treating Dravet syndrome
US20220023316A1 (en) Methods for the treatment of depression
KR20190086709A (ko) 가복사돌로 주의력 결핍/과잉행동 장애를 치료하는 방법들
US20120046302A1 (en) Methods of treating cns disorders
WO2010126527A1 (en) Methods of treating cns disorders
HK40003594A (en) Methods of treating behavioral syndromes using pipradrol
CN112930182A (zh) 加波沙朵用于治疗图雷特综合征、抽搐和口吃的用途
AU2024204318A1 (en) Treatment of Post-Traumatic Syndrome Disorder
HK1170429B (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200522

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210615

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220201